Cargando…
Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases
There have been reports of rare de novo glomerular diseases following vaccination for coronavirus disease 2019 (COVID-19). We report two cases of anti-glomerular basement membrane (GBM) disease in previously healthy females after Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19). The first case...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710461/ https://www.ncbi.nlm.nih.gov/pubmed/36465571 http://dx.doi.org/10.1159/000525737 |
_version_ | 1784841372108324864 |
---|---|
author | Coorey, Craig Peter Phua, Elaine Chou, Angela Shen, Yvonne Mather, Amanda |
author_facet | Coorey, Craig Peter Phua, Elaine Chou, Angela Shen, Yvonne Mather, Amanda |
author_sort | Coorey, Craig Peter |
collection | PubMed |
description | There have been reports of rare de novo glomerular diseases following vaccination for coronavirus disease 2019 (COVID-19). We report two cases of anti-glomerular basement membrane (GBM) disease in previously healthy females after Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19). The first case was a 69-year-old female who developed lethargy and anuria approximately 8 weeks after her first dose of Oxford-AstraZeneca COVID-19 vaccine. The second case was a 72-year-old female who developed malaise and diarrhoea approximately 3 weeks after her second dose of Oxford-AstraZeneca COVID-19 vaccine. Both cases had severe acute kidney injury, raised anti-GBM antibody titres, and renal biopsies consistent with anti-GBM disease. Both cases were commenced on haemodialysis and treated with high dose glucocorticoids, cyclophosphamide, and plasmapheresis. Neither patient had recovery of renal function, and both remain dialysis dependent. These cases add to the previously reported cases of anti-GBM disease after mRNA COVID-19 vaccination. As more COVID-19 vaccinations are administered worldwide, it would be important for clinicians to be aware of this possible association, and continued surveillance is warranted. |
format | Online Article Text |
id | pubmed-9710461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-97104612022-12-01 Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases Coorey, Craig Peter Phua, Elaine Chou, Angela Shen, Yvonne Mather, Amanda Case Rep Nephrol Dial Case Series There have been reports of rare de novo glomerular diseases following vaccination for coronavirus disease 2019 (COVID-19). We report two cases of anti-glomerular basement membrane (GBM) disease in previously healthy females after Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19). The first case was a 69-year-old female who developed lethargy and anuria approximately 8 weeks after her first dose of Oxford-AstraZeneca COVID-19 vaccine. The second case was a 72-year-old female who developed malaise and diarrhoea approximately 3 weeks after her second dose of Oxford-AstraZeneca COVID-19 vaccine. Both cases had severe acute kidney injury, raised anti-GBM antibody titres, and renal biopsies consistent with anti-GBM disease. Both cases were commenced on haemodialysis and treated with high dose glucocorticoids, cyclophosphamide, and plasmapheresis. Neither patient had recovery of renal function, and both remain dialysis dependent. These cases add to the previously reported cases of anti-GBM disease after mRNA COVID-19 vaccination. As more COVID-19 vaccinations are administered worldwide, it would be important for clinicians to be aware of this possible association, and continued surveillance is warranted. S. Karger AG 2022-11-22 /pmc/articles/PMC9710461/ /pubmed/36465571 http://dx.doi.org/10.1159/000525737 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Case Series Coorey, Craig Peter Phua, Elaine Chou, Angela Shen, Yvonne Mather, Amanda Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases |
title | Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases |
title_full | Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases |
title_fullStr | Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases |
title_full_unstemmed | Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases |
title_short | Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases |
title_sort | anti-gbm disease after oxford-astrazeneca chadox1 ncov-19 vaccination: a report of two cases |
topic | Case Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710461/ https://www.ncbi.nlm.nih.gov/pubmed/36465571 http://dx.doi.org/10.1159/000525737 |
work_keys_str_mv | AT cooreycraigpeter antigbmdiseaseafteroxfordastrazenecachadox1ncov19vaccinationareportoftwocases AT phuaelaine antigbmdiseaseafteroxfordastrazenecachadox1ncov19vaccinationareportoftwocases AT chouangela antigbmdiseaseafteroxfordastrazenecachadox1ncov19vaccinationareportoftwocases AT shenyvonne antigbmdiseaseafteroxfordastrazenecachadox1ncov19vaccinationareportoftwocases AT matheramanda antigbmdiseaseafteroxfordastrazenecachadox1ncov19vaccinationareportoftwocases |